NCT03881098
The Lung PCA: A Multi-Dimensional Atlas of Pulmonary Premalignancy
Active, Not Recruiting
NAAges 18+InterventionalScreeningUniversity of Colorado, DenverInvestigator-initiated
~240 participants
Updated 2026-06-03 on ClinicalTrials.gov
What's tested:BronchoscopiesSputum SampleVenipuncture
At a glance
Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Determine Genomic Features of Pre-Malignant Lesions (PML) via Bronchoscopic Biopsy
Measured over Start of study to post baseline bronchoscopy, up to two years
+1 more outcome measured
Conditions
Where it's being run
2 sites across 1 statesColorado2
Study leadership
- Robert Keith, MD · PRINCIPAL_INVESTIGATOR · University of Colorado, Denver
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Pre-existing bronchoscopic documentation of persistence of or progression to high grade dysplasia at two or more airway sites.
Endobronchial dysplasia (squamous metaplasia/mild dysplasia, score \> 3) at \> 3 airway sites.
High grade bronchial dysplasia (moderate dysplasia or worse, score \> 5)
What this trial measures
- Determine Genomic Features of Pre-Malignant Lesions (PML) via Bronchoscopic BiopsyStart of study to post baseline bronchoscopy, up to two years
Prospective data collection of histologic specimens for the purposes of reducing lung cancer mortalities.
- Determine Microenvironmental Features of Lung Pre-Malignant Lesions (PML) via Bronchoscopic BiopsyStart of study to post baseline bronchoscopy, up to two years
Prospective data collection of histologic specimens for the purposes of reducing lung cancer mortalities.